Glaxosmithkline Intellectual Property Development Limited

Michael P Demartino

Mui Cheung

Chengde Wu

Joshi M Ramanjulu

Hilary Schenck Eidam

Haiyu Yu

Linda N Casillas

Joseph J Romano

Zhen Gong

Huiping Amy Guan

Donghui Qin

Adam Kenneth Charnley

Gren Z Wang

Pamela A Haile

Patrick M Eidam

Ami Lakdawala Shah

Zhiliu Zhang

John F Mehlmann

Xiaoyang Dong

Michael Jonathan Bury

Biswajit Kalita

Haiying Yang

Robert W Marquis

Robert R Singhaus

Jeffrey Axten

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

Compounds as rearranged during transfection (RET) inhibitors

Disclosed are compounds that are inhibitors of RIP2 kinase and methods of making and using the same.

Quinazolines as kinase inhibitors

Growing community of inventors

King of Prussia, PA, United States of America

Michael P Demartino